Folate receptor targeted delivery of paclitaxel to breast cancer cells via folic acid conjugated graphene oxide grafted methyl acrylate nanocarrier

Vinothini, Kandasamy; Rajendran, Naresh Kumar; Ramu, A.; Nandhakumar, E.; Rajan, Mariappan

doi:10.1016/j.biopha.2018.12.008

Cited by 100 publications

(41 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, mitotic cells are most sensitive to PTX [161,162]. A perspective option to increase the specificity of PTX in the recognition of BC cells seems to be the application of nanocarriers conjugated with particles that target receptors over-expressed in BC cells [163]. Importantly, the advantages of the development of novel strategies to enhance the efficacy of PTX include the targetability, toxicity, and selectivity toward cancer cells [148].…”

Section: Discussionmentioning

confidence: 99%

Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer

et al. 2019

View full text Add to dashboard Cite

Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer (BC). Unfortunately, the resistance of BC to PTX treatment is a great obstacle in clinical applications and one of the major causes of death associated with treatment failure. Factors contributing to PTX resistance, such as ABC transporters, microRNAs (miRNAs), or mutations in certain genes, along with side effects of PTX including peripheral neuropathy or hypersensitivity associated with the vehicle used to overcome its poor solubility, are responsible for intensive research concerning the use of PTX in preclinical and clinical studies. Novelties such as albumin-bound PTX (nab-PTX) demonstrate a progressive approach leading to higher efficiency and decreased risk of side effects after drug administration. Moreover, PTX nanoparticles for targeted treatment of BC promise a stable and efficient therapeutic intervention. Here, we summarize current research focused on PTX, its evaluations in preclinical research and application clinical practice as well as the perspective of the drug for future implication in BC therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Many researchers showed the effect of loading PTX on nanocarriers in apoptosis induction. [48][49][50] Figure 7a-e demonstrates the cell apoptosis for the samples including control, UÀ PTX, PTX NCs, and PTXÀ CMCS NPs. It is obvious that the lowest cell death possesses to the control group with 0.687%, 2.103% of early and late apoptosis, respectively (Figure 7a).…”

Section: Cell Apoptosismentioning

confidence: 99%

Fabrication of Carboxymethyl Chitosan Nanoparticles to Deliver Paclitaxel for Melanoma Treatment

et al. 2020

View full text Add to dashboard Cite

In the present study, the effectiveness of paclitaxel nanocrystals (PTX NCs) encapsulated in carboxymethyl chitosan (CMCS) nanoparticles (CMCS−PTX NPs) as an anticancer drug is evaluated. The CMCS nanoparticles are produced via a cross‐junction microfluidic device where the PTX/CMCS concentration and flow rates in the device are optimized. The dynamic light scattering data show that the PTX NCs have a median diameter size of 230±90 nm, while the size of CMCS−PTX NPs is roughly 270±30 nm. The zeta‐potential result indicates less negative surface charge for the CMCS−PTX NPs as compared to the PTX NCs. Moreover, scanning electron microscopy micrographs, differential scanning calorimetry thermograms, and X‐ray diffraction patterns reveal that the physicochemical properties of the drug remain unaltered after perfusion through the microfluidic device. Cytotoxicity and cell endocytosis of PTX NCs and CMCS−PTX NPs are evaluated in vitro using G361 melanoma‐positive skin cells. The results reveal that the CMCS−PTX NPs increase the cellular uptake and cytotoxicity compared to the PTX NCs alone. In addition, the antitumor effect of CMCS−PTX NPs on B16 melanoma indicates the great potential of CMCS as a promising nano‐carrier for PTX NCs drug with potent inhibitory effect on the tumor growth.

show abstract

“…The release rate of pH 5.5 and pH 6.8 exhibits 5-ALA was $55.94%, $32.90% and DOX $23.27%, $13.0%, respectively. The pH influenced the release of the drug since the carrier behavior has significant advantages through cancer cell microenvironment in acidic nature surroundings in cancer cells (Vinothini et al, 2019).…”

Section: In Vitro Drug-releasing Studiesmentioning

confidence: 99%